References
- AndesDRKiemSCraigWAIn vivo pharmacodynamic activity of a new carbapenem, doripenem, against multiple bacteria in a murine thigh infection model Abstract A-3082003Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and ChemotherapyChicago, ILWashington DCAmerican Society for Microbiology
- BhavnaniSMHammelJPCirincioniBBPK-PD target attainment with Monte Carlo simulation as decision support of Phase 2/3 dosing strategies for clinical development of doripenem Abstract A-112003Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and ChemotherapyChicago, ILWashington DCAmerican Society for Microbiology
- BhavnaniSMHammelJPCirincioneBBUse of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenemAntimicrob Agents Chemother2005493944716127078
- BossoJAThe antimicrobial armamentarium: evaluating current and future treatment optionsPharmacotherapy20052555S62S16178676
- FritscheTRStilwellMGJonesRNAntimicrobial activity of doripenem (S-4661): a global surveillance report (2003)Clin Microbiol Infect2005119748416307551
- GeYWiklerMASahmDFIn vitro antimicrobial activity of doripenem, a new carbapenemAntimicrob Agents Chemother20044813848615047550
- JonesRNHuynhHKBiedenbachDJDoripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluationsJ Antimicrob Chemother2004a541445415190031
- JonesRNHuynhHKBiedenbachDJActivities of doripenem (S-4661) against drug-resistant clinical pathogensAntimicrob Agents Chemother2004b4831364015273134
- MikamoHIzumiKHuaYXIn vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogensJ Antimicrob Chemother200046471410980177
- MoriMHikidaMNishiharaTComparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-IJ Antimicrob Chemother199637103468737157
- MusthaqSGeYLivermoreDMComparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceaeand Acinetobacter spp with characterized β-lactamasesAntimicrob Agents Chemother2004a4813139
- MusthaqSGeYLivermoreDMDoripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potentialAntimicrob Agents Chemother2004b48308692
- ThyeDAKilfoilTLeightonAA phase I study to evaluate safety, tolerability and pharmacokinetics in a Western healthy volunteer population Abstract A212003Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and ChemotherapyChicago, ILWashington DCAmerican Society for Microbiology
- TraczewskiMMBrownSDIn vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patientsAntimicrob Agents Chemother2006508192116436756
- TsujiMIshiiYOhnoAIn vitro and in vivo antibacterial activities of S-4661, a new carbapenemAntimicrob Agents Chemother1998429499449267